CBG and high blood pressure: what has science discovered?

High blood pressure, one of the most common cardiovascular conditions in the world, has gained a new chapter in cannabinoid research. A study published in the scientific journal Molecules, in October 2026, and reported on the portal NewsWeed, identified effects of cannabigerol (CBG) on blood pressure, blood vessel relaxation, and blood clot formation. The results are promising, but do not yet prove therapeutic benefits in humans.

The research was conducted by scientists from the Medical University of Białystok, in Poland, and investigated how this non-intoxicating compound from cannabis interferes with different mechanisms related to cardiovascular health.

How does CBG influence high blood pressure?

To investigate the cardiovascular effects of cannabigerol, researchers conducted experiments with two groups of rats: spontaneously hypertensive animals and others with normal blood pressure.

CBG was administered intravenously in three dosages: 1, 3, and 10 mg/kg. The results pointed to a reduction in blood pressure and heart rate proportional to the dose used.

Among the hypertensive animals, the highest concentration caused an average reduction of 27 mmHg in systolic pressure and 29 mmHg in diastolic pressure. Heart rate also decreased by approximately 23 beats per minute.

The researchers observed that the response was more pronounced in the systolic pressure of hypertensive animals. However, the effect remained relatively short-lived, with differences in response duration between the groups.

It is important to emphasize that these results were observed in anesthetized animals and do not represent a demonstration of efficacy against high blood pressure in patients.

Medical cannabis and cardiovascular health: what happens in the vessels?

In addition to blood pressure, the study investigated the ability of CBG to promote the relaxation of blood vessels, a phenomenon known as vasorelaxation.

To this end, samples of the aorta and small mesenteric arteries of the animals were analyzed.

The results showed that the cannabinoid promoted concentration-dependent vascular relaxation. In small mesenteric arteries, the maximum response reached approximately 98% in animals with normal blood pressure and 73% in hypertensive ones.

This mechanism draws attention because the resistance offered by blood vessels to the passage of blood is directly involved in blood pressure regulation.

The scientists also identified possible mechanisms of action involving both the regulation of the central nervous system and a direct effect on blood vessels.

Even so, the molecular processes involved still need to be better clarified.

[LEARN MORE: Cannabis and cardiovascular diseases: what recent studies say]

Can CBG and CBD interfere with blood clot formation?

Another relevant result involved platelet aggregation, the process in which platelets clump together to form blood clots.

Although essential to control bleeding, excessive activation of these cells can favor the formation of thrombi and increase the risk of cardiovascular complications.

In this stage, researchers used human blood samples in laboratory experiments to evaluate the effects of CBG, cannabidiol (CBD), and the combination of both compounds.

The results indicated that both were able to inhibit collagen-induced platelet aggregation and reduce the release of substances related to the activation of these cells.

The combination of CBG and CBD also showed relevant inhibitory effects. Under certain experimental conditions, the results were comparable or superior to those observed with acetylsalicylic acid (aspirin), used as a reference in the laboratory.

This comparison, however, does not mean that cannabinoids have efficacy equivalent to aspirin in patients. The experiments were performed outside the living organism and do not demonstrate safety or clinical benefit.

[LEARN MORE: Understand how cannabinoids act in the human body]

Can CBG be used in the treatment of hypertension?

Despite the findings, it is still too early to consider CBG a therapeutic alternative for people with hypertension.

The research has two major limitations: the effects on blood pressure were evaluated in rats, while the platelet experiments used human blood samples in a laboratory.

This means that the results cannot be directly replicated or generalized to patients using cannabis-based products orally or via inhalation.

The researchers also did not assess the effects of long-term use, clinical tolerability, or potential interactions with antihypertensive and anticoagulant medications.

Therefore, additional studies and human clinical trials will still be needed to understand the therapeutic potential of CBG and its cardiovascular safety.

For now, the discovery expands knowledge about cannabinoids and opens up new avenues for scientific investigation.

For those living with high blood pressure, the guidance remains to maintain medical follow-up and not substitute or discontinue prescribed medications on their own.